Sandoz, >98% (HPLC), powder
Application
Sandoz 58-035 was used to induce simultaneous activation of unfolded protein response (UPR) and pattern recognition receptors (PRRs) in mouse peritoneal macrophages.3
Biochem/physiol Actions
Sandoz 58-035 inhibits the accumulation of cholesteryl esters and inhibits the esterification of cholesterol by 95% in arterial smooth muscle cells in culture.1 It does not affect the triglyceride metabolism by the gut.2
Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
5, 25 mg in glass bottle
| Colour | white |
|---|---|
| Quality Level | 100 |
| InChI key | NBYATBIMYLFITE-UHFFFAOYSA-N |
| InChI | 1S/C30H47NOSi/c1-5-6-7-8-9-10-11-15-23-33(3,4)24-22-30(32)31-29(28-16-13-12-14-17-28)25-27-20-18-26(2)19-21-27/h12-14,16-21,29H,5-11,15,22-25H2,1-4H3,(H,31,32) |
| Manufacturer | SIGMA-ALDRICH |
| Form | powder |
| Assay | >98% (HPLC) |
There are no downloads for this product.
